Companies in #TCR-T Cell Therapy
Found 1 company operating in this sector.
TScan Therapeutics is a clinical-stage immunotherapy company developing a portfolio of TCR-T cell therapies for hematologic malignancies and solid tumors. The company's lead program TSC-101 is in the ALLOHA Phase 1 study for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, with positive initial data from Cohort C reported in 2026 showing 11 of 14 dosed patients achieving complete donor chimerism. TScan is preparing TSC-101 for a planned Phase 3 study in blood cancers as the next value-driving event. The company has also established a Cellares automated-manufacturing agreement for TSC-101 production scalability. TScan is headquartered in Waltham, Massachusetts and trades on the Nasdaq Capital Market under the symbol TCRX.